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ABSTRACT
Background: Regular physical activity contributes to the prevention of cancer, cardiovascular disease, and other
chronic diseases. However, the frequency of physical activity often declines with age, particularly among the elderly.
Thus, we investigated the effects of daily walking on mortality among younger-elderly men (65–74 years) with or
without major critical diseases (heart disease, cerebrovascular disease, or cancer).
Methods: We assessed 1239 community-dwelling men aged 64/65 years from the New Integrated Suburban
Seniority Investigation Project. We estimated hazard ratios (HRs) of all-cause mortality and 95% conﬁdence intervals
(CIs) according to daily walking duration and adjusted for potential confounders, including survey year, marital
status, work status, education, smoking and drinking status, BMI, regular exercise, regular sports, sleeping time,
medical status, disease history, and functional capacity.
Results: For men without critical diseases, mortality risk declined linearly with increased walking time after
adjustment for confounders (Ptrend = 0.018). Walking ≥2 hours/day was signiﬁcantly associated with lower all-cause
mortality (HR 0.49; 95% CI, 0.27–0.90). For men with critical diseases, walking 1–2 hours/day showed a protective
effect on mortality compared with walking <0.5 hours/day after adjustment for confounders (HR 0.29; 95% CI,
0.06–1.20). Walking ≥2 hours/day showed no beneﬁt on mortality in men with critical diseases, even after adjustment
for confounders.
Conclusions: Different duration of daily walking was associated with decreased mortality for younger-elderly men
with or without critical diseases, independent of sociodemographic and lifestyle factors, BMI, medical status, disease
history, and functional capacity. Incorporating regular walking into daily lives of younger-elderly men may improve
longevity and successful aging.
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INTRODUCTION
There is mounting evidence that regular physical activity is
a good indicator of health-related outcomes later in life.1
Regular physical activity has been reported to positively
contribute to primary and secondary prevention of
cardiovascular disease, cancer, hypertension, diabetes, and
other chronic disease events.2 However, age-related declines
in physical activity are common,3 especially for elderly people
with heart disease.2
Walking, a preferred moderate physical activity for the
elderly because of its relative ease and accessibility,4 has been
encouraged to be incorporated into the daily routines of aging
populations to help maintain a physically active lifestyle.5,6
Walking has even been recommended for patients with
existing diseases who are less likely to practice moderate-
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to-vigorous physical activity.7,8 Several reviews and meta-
analyses have elucidated the positive associations between
walking and cardiovascular disease events among the general
population,9–11 and the effects of these beneﬁts on all-cause or
cardiovascular mortality in elderly populations have also been
demonstrated.12–14 Collectively, looking at a broad spectrum
of ages might fail to clarify the beneﬁcial effects of walking
on health-related issues among the elderly; it is unreasonable
to apply the results observed among younger or middle-aged
adults to an older population,15 as pre-existing illnesses in the
study population might enhance the bias in terms of health
outcomes.9 Moreover, although some previous studies have
suggested that cardiovascular disease or diabetes patients are
likely to obtain health beneﬁts through regular walking,11 data
on secondary prevention is still lacking. Examination of these
issues can improve our understanding of the role walking
may play in the presence or absence of established chronic
conditions in an elderly population.
Therefore, the current study was designed to investigate the
health beneﬁts of daily walking on mortality among younger-
elderly men (aged 65–74 years) with or without heart disease,
cerebrovascular disease, or cancer to elucidate how walking
could aid in successful aging and longevity.
METHODS
Study population
The data were derived from the New Integrated Suburban
Seniority Investigation Project, an on-going age-speciﬁc
prospective cohort study. The rationale and design of the
study has been described previously in detail.16 Brieﬂy, based
on the basic resident registry, community-dwelling elderly
who were age 64 at the beginning of each given survey year in
a city in central Japan were invited via letter to take part in a
free comprehensive medical examination and complete a self-
administrated questionnaire each June from 1996 through
2005. A total of 3073 participants (1548 men and 1525 women)
agreed to register as cohort members. In the present study, 1239
men were selected as the study sample, after excluding those
who entered the study after 2003 (304 subjects) because their
10-year follow-up had not been completed, and men with
missing data on daily walking (5 subjects).
Consent to complete the questionnaire was obtained orally
by an opt-out approach from 1996 to 2001, and in writing
by an opt-in approach thereafter.16 The study protocol was
approved by the Ethics Committees of Nagoya University
Graduate School of Medicine, the National Center for
Geriatrics and Gerontology of Japan, Aichi Medical
University School of Medicine, and Hokkaido University
Graduate School of Medicine.
Baseline assessment
Baseline data were obtained through self-administered
questionnaires and objective measurements taken during the
health examination. Walking duration was assessed based on
self-reported time spent daily walking by asking “How many
hours a day do you walk?”. The available options included
<30 minutes/day, 30 minutes to 1 hour/day, 1–2 hours/day
and ≥2 hours/day. Time spent on daily walking was clearly
deﬁned in the questionnaire to include walking for exercise,
working, and household, social, or other activities. The term
“major critical diseases” was deﬁned as any heart disease,
cerebrovascular disease, or cancer (the three leading causes of
death in Japan), which account for more than 50% of the
mortality of elderly aged 65 years.17 Information on these
diseases was also obtained from the questionnaire, in which
subjects recorded their current treatment situation for existing
diseases and the age when a physician diagnosed them with
these diseases.
Sociodemographic and lifestyle factors included marital
status (married, divorced, widow, single, or other), education
(elementary school, junior high school, high school, junior
college, university, or other), work status (not working or
working), smoking status (never, past, or current), drinking
status (never or current), regular exercise (never, <once/week,
or ≥once/week), participation in regular sports (yes or no),
and sleeping time (<7, 7–8, or >8 hours/day). Body mass
index (BMI) was calculated and categorized into three groups
(<18.5, 18.5–24.9, or ≥25 kg/m2). Medical status included
hypertension, hyperlipidaemia, and diabetes mellitus.
Hypertension was deﬁned as a measured systolic blood
pressure ≥140mmHg, diastolic blood pressure ≥90mmHg,
self-reported hypertension, or use of antihypertensive
medication. Hyperlipidaemia was deﬁned as a total choles-
terol level ≥220mg/dL or self-reported hyperlipidaemia.
Diabetes mellitus was deﬁned as haemoglobin A1c (HbA1c)
≥6.5% (according to the National Glycohemoglobin
Standardization Program [NGSP] method), fasting plasma
glucose ≥126mg/dL, or self-reported diabetes mellitus. In the
New Integrated Suburban Seniority Investigation Project,
HbA1c was measured according to Japan Diabetes Society
(JDS) units. We transformed these results to NGSP values
based on the conversion formula: NGSP (%) = 1.02 * JDS
(%) + 0.25%.18 History of disease included self-reported
history of clinically recognized chronic bronchitis, neuralgia/
osphyalgia, or arthritis, or use of medication for these
diseases. The short-form Geriatric Depression Scale (GDS-
15) is a self-rated depression-screening tool for the elderly,
and a total score of 6 or higher was treated as signiﬁcant
depressive tendency.19–21 The Tokyo Metropolitan Institute
of Gerontology (TMIG) Index of Competence was used to
evaluate intellectual, physical, and social function capacity,
and possible total scores ranged from 0 to 13, with a higher
score indicating a greater competence level.22 Gait speed was
used to assess physical function as in previous studies, where
it has been applied to evaluate the physical function of elderly
populations with intellectual disability23 and community-
dwelling populations.24 Gait speed was categorized into three
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groups (slow, normal, and fast) by asking, “How fast have you
walked over the past year?”. Although our data were self-
reported gait speed rather than objective gait speed, we
checked the validity of self-reported gait speed in our previous
study.25
Follow-up
Dates for death and relocation out of the city were obtained
from the basic resident registry. All participants were followed
until death from any cause, relocation, or the last day of
the year when they reached 75 years of age, whichever
occurred ﬁrst.
Statistical analysis
Descriptive statistics were used to summarize the baseline
characteristics of participants according to time spent daily
walking and the morbidity of major critical diseases (Table 1).
If the data were continuous, they were categorized according
to standard clinical reference values. A Cox proportional
hazard model was applied to estimate the hazard ratios (HRs)
Table 1. Baseline characteristics according to daily walking and morbidity of major critical diseases (n = 1239)


















Married 178 (97.8) 321 (95.0) 228 (93.1) 204 (92.3) 54 (96.4) 98 (98.0) 54 (100.0) 42 (97.7)
Other 3 (1.6) 17 (5.0) 17 (6.9) 17 (7.7) 2 (3.6) 2 (2.0) — 1 (2.3)
Work status
Not working 87 (47.8) 135 (39.9) 116 (47.3) 64 (29.0) 32 (57.1) 46 (46.0) 28 (51.9) 14 (32.6)
Working 94 (51.6) 201 (59.5) 128 (52.2) 153 (69.2) 23 (41.1) 51 (51.0) 26 (48.1) 28 (65.1)
Highest education
Junior school or less 46 (25.3) 87 (25.7) 69 (28.2) 103 (46.6) 13 (23.2) 17 (17.0) 15 (27.8) 15 (34.9)
High school 76 (41.8) 127 (37.6) 84 (34.3) 81 (36.7) 27 (48.2) 41 (41.0) 16 (29.6) 18 (41.9)
College or more 60 (33.0) 124 (36.7) 91 (37.1) 37 (16.7) 16 (28.6) 42 (42.0) 23 (42.6) 10 (23.3)
Smoking status
Never 35 (19.2) 64 (18.9) 47 (19.2) 48 (21.7) 10 (17.9) 20 (20.0) 8 (14.8) 6 (14.0)
Past 86 (47.3) 170 (50.3) 104 (42.4) 85 (38.5) 28 (50.0) 56 (56.0) 31 (57.4) 25 (58.1)
Current 61 (33.5) 104 (30.8) 93 (38.0) 88 (39.8) 18 (32.1) 24 (24.0) 15 (27.8) 12 (27.9)
Drinking status
Never 58 (31.9) 109 (32.2) 71 (29.0) 65 (29.4) 20 (35.7) 31 (31.0) 19 (35.2) 17 (39.5)
Current 124 (68.1) 229 (67.8) 174 (71.0) 156 (70.6) 36 (64.3) 69 (69.0) 35 (64.8) 25 (58.1)
BMI (kg/m2)
<18.5 13 (7.1) 9 (2.7) 13 (5.3) 10 (4.5) 1 (1.8) 6 (6.0) 2 (3.7) 1 (2.3)
18.5–25 121 (66.5) 255 (75.4) 184 (75.1) 162 (73.3) 35 (62.5) 68 (68.0) 40 (74.1) 29 (67.4)
≥25 48 (26.4) 74 (21.9) 48 (19.6) 49 (22.2) 20 (35.7) 26 (26.0) 12 (22.2) 13 (30.2)
Regular exercise
Never 99 (54.4) 115 (34.2) 78 (31.8) 109 (49.3) 35 (62.5) 32 (32.0) 13 (24.1) 19 (44.2)
<once/week 25 (13.7) 37 (11.0) 22 (9.0) 21 (9.5) 5 (8.9) 6 (6.0) 2 (3.7) 5 (11.6)
≥once/week 58 (31.9) 184 (54.8) 145 (59.2) 91 (41.2) 16 (28.6) 62 (62.0) 39 (72.2) 19 (44.2)
Regular sports
No 92 (50.8) 141 (42.3) 98 (40.0) 129 (58.4) 39 (70.9) 42 (42.0) 19 (35.2) 21 (48.8)
Yes 89 (49.2) 192 (57.7) 144 (58.8) 90 (40.7) 16 (29.1) 58 (58.0) 35 (64.8) 22 (51.2)
Sleeping time
<7h/d 86 (47.3) 157 (46.6) 101 (41.2) 101 (45.7) 23 (41.8) 41 (41.0) 19 (35.2) 15 (34.9)
7–8h/d 70 (38.5) 139 (41.2) 113 (46.1) 89 (40.3) 21 (38.2) 47 (47.0) 29 (53.7) 23 (53.5)
≥8h/d 26 (14.3) 41 (12.2) 31 (12.7) 31 (14.0) 11 (20.0) 12 (12.0) 6 (11.1) 5 (11.6)
Medical status
Hypertension 100 (54.9) 170 (50.3) 134 (54.7) 110 (49.8) 28 (50.0) 57 (57.0) 30 (55.6) 23 (53.5)
Hyperlipidemia 66 (36.3) 116 (34.4) 91 (37.1) 68 (30.8) 15 (27.3) 31 (31.0) 19 (35.2) 14 (33.3)
Diabetes Mellitus 27 (14.9) 45 (13.4) 50 (20.4) 21 (9.5) 12 (21.8) 21 (21.0) 12 (22.2) 5 (11.9)
History of disease 26 (14.3) 43 (12.7) 28 (11.4) 25 (11.3) 8 (14.3) 15 (15.0) 3 (5.6) 5 (11.6)
Gait speed
Slow 44 (24.3) 33 (9.8) 16 (6.5) 20 (9.1) 16 (29.1) 13 (13.0) 10 (18.5) 3 (7.0)
Normal 125 (69.1) 250 (74.0) 193 (78.8) 168 (76.0) 38 (69.1) 77 (77.0) 38 (70.4) 34 (79.1)
Fast 12 (6.6) 55 (16.3) 36 (14.7) 33 (14.9) 1 (1.8) 10 (10.0) 6 (11.1) 6 (14.0)
GDS-15 score
<6 139 (76.4) 276 (81.7) 197 (80.4) 182 (82.4) 36 (65.5) 77 (77.0) 46 (85.2) 34 (79.1)
≥6 43 (23.6) 62 (18.3) 47 (19.2) 35 (15.8) 19 (34.5) 23 (23.0) 8 (14.8) 9 (20.9)
TMIG score
≤10 33 (18.1) 42 (12.4) 34 (13.9) 27 (12.2) 10 (18.2) 13 (13.0) 6 (11.1) 9 (20.9)
>10 149 (81.9) 296 (87.6) 211 (86.1) 193 (87.3) 45 (81.8) 87 (87.0) 48 (88.9) 34 (79.1)
GDS-15, Geriatric Depression Scale (Short Form); h/d, hours/day; TMIG, Tokyo Metropolitan Institute of Gerontology Index of Competence.
All values shown are as n (%). The proportion of each variable does not always add up to 100% owing to missing data.
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and 95% conﬁdence intervals (CIs) for all-cause mortality
based on time spent walking for men with or without major
critical diseases. The proportional hazard assumption was
tested by log-log plots. The interaction between daily walking
and exercise, or daily walking and sports participation, was
examined by the likelihood-ratio test. In multivariate analysis,
we created three models to adjust for potential confounders.
Model I adjusted for survey year; model II included survey
year, sociodemographic and lifestyle factors (marital status,
working status, education, smoking and drinking status,
participation in regular exercise, regular sports, and sleeping
time), and BMI; and model III adjusted for all the confounders
in model II as well as medical status (hypertension,
hyperlipidaemia, and diabetes mellitus), history of disease
(chronic bronchitis, neuralgia/osphyalgia, and/or arthritis),
and functional capacity (gait speed, GDS-15, and TMIG
scores). Sensitivity analyses were conducted by excluding
subjects who died or that dropped out of the study for any
reason (eg, relocated or refused follow-up) within the ﬁrst
three years (model IV), or by excluding subjects who were
diagnosed with heart disease, cerebrovascular disease, or
cancer at age 63, 64, or 65 (model V). We also tested for linear
trends in the categories of time spent walking in the Cox
proportional hazard models.
All P values were based on two-tailed tests of signiﬁcance;
P < 0.05 was taken to be statistically signiﬁcant. All statistical
analyses were performed using JMP Clinical 5 for Microsoft
Windows (SAS Institute Inc., Cary, NC, USA).
RESULTS
During the total 12 829 person-years of follow-up, 175 men
died. Table 1 summarizes the baseline characteristics of the
participants according to daily time spent walking and absence
or presence of major critical diseases. Of all 1239 men,
253 reported a history of heart disease (161 events),
cerebrovascular disease (67 events), or cancer (42 events).
For men without major critical diseases, those walking ≥2
hours/day were less likely to be married and more likely to
have a job, a lower education level, and a lower prevalence
of diabetes mellitus, and walked faster than men walking <0.5
hours/day. For men with major critical diseases, those who
walked 1–2 hours/day had a higher education level, performed
more regular exercise and sports per week, had a lower
prevalence of diabetes mellitus, and had fewer depressive
symptoms and higher TMIG scores than men in other walking
groups. Table 2 presents the HRs of daily walking on
mortality and 95% CIs for all the males. After adjustment
for survey year, sociodemographic and lifestyle factors, BMI,
medical status, history of disease, and functional capacity,
walking ≥2 hours/day was signiﬁcantly associated with all-
cause mortality in all men (HR 0.52; 95% CI, 0.30–0.88), and
the association displayed a linear trend (Ptrend = 0.009).
Table 3 shows the HRs of daily walking on mortality and
95% CIs stratiﬁed by those with or without major critical
diseases. For men without major critical diseases, the risk of
death linearly declined as walking duration increased after
adjustment for survey year, sociodemographic and lifestyle
factors, and BMI (Ptrend = 0.012). Further adjustment for
medical status, history of disease, and functional capacity
did not alter the initial trend (Ptrend = 0.018) and led to a
signiﬁcant association of mortality with walking ≥2 hours/day
(HR 0.49; 95% CI, 0.27–0.90). Men with major critical
diseases presented a different association from the total
sample of men. Walking 1–2 hours/day showed a protective
effect on mortality after adjustment for survey year,
sociodemographic and lifestyle factors, and BMI (model II:
HR 0.30; 95% CI, 0.07–1.11) compared with walking <0.5
hours/day. Following adjustment for medical status, history
of disease, and functional capacity (model III), walking 1–2
hours/day was still associated with decreased mortality (HR
0.29; 95% CI, 0.06–1.20). Walking ≥2 hours/day did not show
substantial beneﬁts for mortality in men with major critical
diseases after full adjustment for confounding factors (HR
0.82; 95% CI, 0.20–3.24), and a linear trend was not observed.
In the sensitivity analyses, after excluding participants who
died or that were censored within the ﬁrst 3 years (model IV),
walking ≥2 hours/day was still inversely associated with
mortality among men without major critical diseases (HR
0.40; 95% CI, 0.20–0.76), and signiﬁcantly decreased
mortality was observed among those with major critical
diseases within the intermediate walking duration of 1–2
Table 2. Association of daily walking with mortality in all participants
<0.5h/d 0.5–1h/d 1–2h/d ≥2h/d P for trend
Person-years 2379 4558 3100 2792
Deaths 42 67 40 26
Model I 1.00 0.82 (0.56, 1.22) 0.73 (0.47, 1.12) 0.53 (0.32, 0.86)* 0.010*
Model II 1.00 0.87 (0.59, 1.32) 0.72 (0.45, 1.13) 0.49 (0.29, 0.82)* 0.005*
Model III 1.00 0.95 (0.63, 1.46) 0.79 (0.49, 1.27) 0.52 (0.30, 0.88)* 0.009*
CI, conﬁdence interval; h/d, hours/day; HR, hazard ratio.
Values shown are HR (95% CI). *P < 0.05.
Model I adjusted for survey year. Model II adjusted for survey year, marital status, work status, education, smoking and drinking status, BMI, regular
exercise, daily sleeping duration, and regular sports. Model III adjusted for the confounders in model II as well as hypertension, hyperlipidaemia,
diabetes mellitus, chronic bronchitis, neuralagia/osphyalgia, arthritis, gait speed, and GDS-15, and TMIG scores.
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hours/day (HR 0.20; 95% CI, 0.03–0.93). After excluding
subjects who suffered from major critical diseases at the age
of 63, 64, or 65 (model V), this association did not change
substantially among men with major critical diseases (HR
0.17; 95% CI, 0.03–0.96). In addition, we did not observe any
signiﬁcant interactions on mortality between daily walking
and exercise (P = 0.318) or participation in sports (P = 0.229).
DISCUSSION
After follow-up to the age of 75, we observed that daily
walking was associated with a decreased risk of death for
younger-elderly Japanese men, independent of sociodemo-
graphic and lifestyle factors, BMI, medical status, history
of disease, and functional capacity. There was a linear
association between daily walking and all-cause mortality
among men without major critical diseases, while there was a
peak in beneﬁt at an intermediate duration of daily walking for
men with major critical diseases.
To our knowledge, this is the ﬁrst age-speciﬁc cohort study
to elucidate the effect of daily walking on mortality among
younger-elderly men, stratiﬁed by the presence and absence
of heart disease, cerebrovascular disease, and cancer. Our
ﬁndings are consistent with the few existing reports that
mortality from cardiovascular disease,26,27 cancer,28 or all
causes28,29 among older men was decreased with increasing
walking distance or duration. Recent evidence suggests that
daily walking could protect against all-cause mortality among
elderly aged ≥65 years.30 Physically active participants have
been reported to have low levels of inﬂammatory markers
(serum high-sensitivity C-reactive protein and interleukin-6)
that might be responsible for cardiovascular disease or other
age-related diseases.31 It has been suggested that walking
could contribute to improved cardiovascular ﬁtness, reduced
body weight and body fat, and decreased resting diastolic
blood pressure, as well as inﬂuence lipid proﬁles, clotting
factors, and other concomitant risk factors.26,32 Moreover,
circulatory insulin-like growth factor I was reported to be
inversely related to time spent walking among men, which
may partly account for the protective effects of physical
activity against cancer at certain sites in the body.33
The evidence is still unclear in terms of the beneﬁts of time
spent walking on mortality among the elderly with major
critical diseases, although a minimum amount and type of
physical activity has been proposed by the American College
of Sports Medicine (ACSM) and the American Heart
Association (AHA) for elderly individuals with chronic
conditions to prevent other conditions from developing and
assist with therapy for the documented diseases.34 Our
ﬁndings provide new evidence that an intermediate walking
duration (1–2 hours/day) can decrease mortality risk by
70% in younger-elderly community-dwelling men with
cardiovascular disease, cerebrovascular disease, or cancer,
while walking for a longer duration (≥2 hours/day) may not
provide any signiﬁcant beneﬁts in these men. In previous
studies in elderly populations, the largest category of daily
walking was ≥1 hour/day, so the threshold of walking duration
in the elderly with major critical diseases might not be
clear.7,10,29 Our result is consistent with physical activity
recommendations from the ACSM and AHA that older
people with chronic diseases should tailor their activity plan
according to the prescription from physicians to avoid the
risk of inappropriate physical activity.34
There are also some studies concluding the same trend as
our ﬁndings regarding the association between physical
activity intensity and mortality, though there are no previous
Table 3. Association of daily walking with mortality according to morbidity of major critical diseases
Without major critical diseases P for
trend
With major critical diseases P for
trend<0.5 h/d 0.5–1h/d 1–2h/d ≥2h/d <0.5 h/d 0.5–1h/d 1–2h/d ≥2h/d
Person-years 1821 3534 2509 2330 558 1024 592 462
Death Case 32 51 36 20 10 16 4 6
Model I 1.00 0.82 (0.53, 1.28) 0.83 (0.52, 1.35) 0.50 (0.28, 0.86)* 0.023* 1.00 0.85 (0.38, 2.04) 0.35 (0.09, 1.07) 0.75 (0.25, 2.10) 0.189
Model II 1.00 0.94 (0.59, 1.50) 0.85 (0.51, 1.41) 0.48 (0.26, 0.86)* 0.012* 1.00 0.98 (0.37, 2.76) 0.30 (0.07, 1.11) 0.69 (0.19, 2.38) 0.129
Model III 1.00 1.03 (0.64, 1.68) 0.94 (0.56, 1.60) 0.49 (0.27, 0.90)* 0.018* 1.00 0.92 (0.31, 2.94) 0.29 (0.06, 1.20) 0.82 (0.20, 3.24) 0.289
Person-years 1806 3504 2485 2312 555 1016 588 460
Death Case 28 45 31 15 10 14 3 5
Model IV 1.00 1.01 (0.61, 1.70) 0.92 (0.53, 1.63) 0.40 (0.20, 0.76)* 0.006* 1.00 0.78 (0.26, 2.53) 0.20 (0.03, 0.93)* 0.48 (0.11, 2.02) 0.078
Person-years — — — — — 446 705 452 367
Death Case — — — — — 8 9 3 4
Model Va — — — — — 1.00 0.73 (0.21, 2.54) 0.17 (0.03, 0.96)* 0.65 (0.11, 3.20) 0.289
CI, conﬁdence interval; h/d, hours/day; HR, hazard ratio.
Values shown are HR (95% CI); *P < 0.05.
aHR and 95% CI are not shown for men without diseases because these values were equal to those in model III.
Model I adjusted for survey year. Model II adjusted for survey year, marital status, work status, education, smoking and drinking status, BMI, regular
exercise, daily sleeping duration, and regular sports. Model III adjusted for the confounders in model II as well as hypertension, hyperlipidaemia,
diabetes mellitus, chronic bronchitis, neuralagia/osphyalgia, arthritis, gait speed, and GDS-15 and TMIG scores. Model IV excluded subjects who
died or were censored within the ﬁrst three years, and adjusted for all the confounders in model III. Model V excluded subjects who were diagnosed
with heart disease, cerebrovascular disease, or cancer at the age of 63, 64, or 65 years and adjusted for all the confounders in model III.
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studies focusing on the association of walking duration with
mortality for older populations with chronic diseases. For
example, the British Regional Heart Study has demonstrated
that regular light or moderate intensity physical activity, such
as walking, is likely to be sufﬁcient to achieve signiﬁcant
beneﬁts, while sports or vigorous activities conferred no
additional beneﬁt for older men with established cardio-
vascular disease35 and coronary heart disease.36 A systematic
review concerning cancer survivors showed that decreased
mortality from colon cancer was associated with 6 hours
of walking per week, and more vigorous exercise may
not improve survival.37 However, the precise mechanism
explaining why long duration of physical activity confers no
additional beneﬁts for the elderly is still not fully understood.38
Presumably, in the context of age- and disease-related
heterogeneity in cardiorespiratory capacity, musculoskeletal
ﬁtness, medical comorbidities, and performance in activities of
daily living, an intermediate walking duration, regardless of
walking intensity, might be an optimal amount of time for men
with major critical diseases. This amount of time might be
appropriate for their capacity to undertake physical activities,
while any longer is unlikely to yield any mortality beneﬁt.
Strengths and limitations
Our age-speciﬁc cohort study effectively eliminated the
inﬂuence of age on mortality because age is a major risk
factor for mortality and reduced physical activity.1 We
conducted an extensive range of adjustments for
sociodemographic and lifestyle factors, BMI, medical status,
history of disease, and functional capacity, which isolated, as
far as possible, an independent association between daily
walking duration and mortality.4 We also checked the
interaction between walking and exercise, as well as
walking and regular sports, and adjusted for these two kinds
of physical activity to keep the independent association
between walking and all-cause mortality.
Some limitations have to be taken into account. First, as a
prospective cohort study rather than a randomized clinical
trial, this study is less likely to show true causality because
the health status of the elderly participants might produce
certain walking habits at baseline or change the level of daily
walking over time, especially for participants with established
major critical diseases who may have contraindications to
participating in physical activities during the initial stage of
disease diagnosis. However, to avoid reverse causality, we
adopted two approaches to support this association. The ﬁrst
was to exclude participants who died or were censored within
the ﬁrst 3 years, thereby eliminating the bias caused by
participants at higher risk of death. The second approach was
to check the age at diagnosis for cardiovascular disease,
cerebrovascular disease, and cancer, and then exclude those
subjects diagnosed with one or more of these diseases at 63,
64, or 65 years of age, thereby decreasing the possibility
that walking duration changed in those with major critical
diseases. Second, the sample size for men with major critical
diseases was small compared with previous analogous studies
that involved physical activity in patients with established
cardiovascular disease or cancer and covered a wide range of
ages in the elderly. However, our study paid speciﬁc attention
to a sub-domain of physical activity (regular walking) and
restricted inclusion to the younger-elderly, which as a whole
limited the enrolment of subjects. Meanwhile, due to the small
sample size of this subgroup, the power of the test may be low,
which may lead to a high possibility of type II error. Further
study is needed to understand this association, with more
attention focused on the younger-elderly with one or more
chronic diseases. Third, our data on walking duration came
from a self-administrated questionnaire rather than an
objective measurement, and the validity of the single-item
questionnaire was not assessed. Self-reported daily walking
duration may be overestimated.39 Finally, information about
walking intensity was lacking in our survey; however, this
will be addressed in a future study.
Conclusion
Our ﬁndings here suggest a theoretical walking duration for
younger-elderly men with or without major critical diseases.
Walking for relatively long periods was associated with a
decrease in all-cause mortality for men without major critical
diseases, while an intermediate walking duration was
beneﬁcial to younger-elderly men with major critical
diseases. These ﬁndings support the view that daily walking
has the potential to contribute to primary and secondary
prevention of heart disease, cerebrovascular disease, cancer,
and other diseases, and might be a promising and effective
prescription of medicine for elderly with chronic conditions.
This may also provide evidence for public health recom-
mendations that incorporating regular walking into daily life
may improve quality of life among the elderly and extend
longevity. Younger-elderly men with one or more chronic
conditions should gradually and regularly practice walking
based on individual abilities and ﬁtness to improve
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